Context:

The Democratic Republic of the Congo’s Ebola outbreak is accelerating, driven in part by a testing shortfall that hinders detection, contact tracing, and isolation. Despite a rapid expansion of testing capacity—from a handful of labs to nineteen—and new diagnostic tools, delays persist and the positive test rate remains high, suggesting under-testing. The outbreak’s spread is complicating by logistical hurdles, security disruptions, and persistent skepticism toward responders, undermining early treatment and containment. Efforts to deploy GeneXpert and new cartridges, plus fast-track diagnostics from the WHO and Gates Foundation, aim to quicken results and decouple decentralized testing from central labs. If diagnostic speed and reach do not improve, momentum toward halting the outbreak is unlikely to resume soon.

Dive Deeper:

• Africa CDC reported the outbreak as the second-worst on record, with cases doubling roughly every 10 days and over 1,800 deaths; the toll is believed to be significantly higher.

• The core problem is the inability to reliably test for Bundibugyo, a rarer Ebola strain, with existing GeneXpert cartridges, which initially detected only the Zaire strain.

• PCR testing remains the only reliable method for Bundibugro detection, but samples must travel long distances to labs, and security-related roadblocks slow turnaround times, sometimes requiring handwritten results to be transported back to centers.

• Lab capacity has expanded to 19 facilities capable of PCR testing, up from just two at the outbreak’s start, yet about 12.5% of tests still exceed a 72-hour result window and roughly 45% of tests are positive, indicating substantial under-testing.

• Solutions under consideration include distributing Bundibugro-detecting GeneXpert cartridges across hospitals and leveraging a whole-Ebola panel approved for DoD use, though accuracy must be validated against PCR results.

• Quantum leaps in diagnostics are being pursued through various channels: the Gates Foundation funding field-ready diagnostics, the WHO fast-tracking eight Ebola tests (including GeneXpert), and RADIONE machines already delivered though limited-per-batch capacity constrains impact.

• Wider testing shortages contribute to patients delaying care and many cases remaining undetected, with home deaths and lack of isolation beds undermining surveillance and containment efforts.